Research by Dr. Gerard Criner and the Temple Lung Center Team Leads to Second FDA Approval of a Minimally Invasive Endobronchial Treatment for Severe Emphysema

For the second time this year, Temple was the lead enroller for a study that led to approval from the FDA for a minimally invasive treatment option for emphysema. Dr. Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center, announced the 12-month results of the EMPROVE study for the Spiration® Valve System back in September. Based upon positive results of that study, for which the Temple Lung Center was lead enroller and Dr. Criner was a principal investigator, the FDA has granted approval for this new treatment under its breakthrough medical devices designation. MD Magazine, BioWorld MedTech, MassDevice.com, Markets Insider, Marketplace, the Pittsburgh Post-Gazette, WFMZ-TV, WBOC-TV and others provided coverage.